Veru Q2 net loss narrows as expenses decline

Overview

• US biopharma firm's fiscal Q2 net loss narrowed year-over-year

• Research and development and administrative expenses both declined from prior year

Outlook

• Company plans to prioritize internal cash for enobosarm development; advancement of sabizabulin depends on new funding

Result Drivers

• EXPENSE REDUCTIONS - Lower research and development and administrative expenses narrowed net loss in Q2

Company press release: ID:nGNX6BHKLg

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Veru Inc is $25.00, about 1,001.3% above its May 12 closing price of $2.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.